Jubilant Pharmova has announced that its Board of Directors approved the unaudited financial results for the quarter and nine months ended December 31, 2025, at a meeting held on February 6, 2026. The pharmaceutical company has filed the consolidated and standalone financial results with stock exchanges and published them in newspapers for public access.

Board Meeting and Approval Process

The Board of Directors meeting was conducted on Friday, February 6, 2026, commencing at 10:30 A.M. and concluding at 12:35 P.M. The board approved both standalone and consolidated unaudited financial results for the third quarter and nine months period ended December 31, 2025, in accordance with Regulation 33 read with Regulation 30 of the SEBI Listing Obligations and Disclosure Requirements Regulations, 2015. The Audit Committee reviewed these results at its meeting held on February 5, 2026.

Newspaper Publication and Public Access

Pursuant to Regulation 30 and Regulation 47 of the SEBI regulations, Jubilant Pharmova submitted copies of published financial results to stock exchanges on February 7, 2026. The company published Quick Response Codes and webpage details in Financial Express (English) and Jansatta & Hindustan (Hindi) newspapers dated February 7, 2026, providing investors easy access to complete financial results.

Regulatory Filings and Documentation

The company has filed comprehensive documentation with both BSE Limited and National Stock Exchange of India Limited. The filings include unaudited financial results for both standalone and consolidated operations, along with limited review reports from statutory auditors Walker Chandiok & Co LLP. The results are also accessible through stock exchange websites and the company's official website.

Upcoming Investor Engagement

Jubilant Pharmova has scheduled physical investor and analyst meetings for February 9, 2026, in Mumbai to discuss the Q3FY26 earnings performance. The meetings, organized by Nuvama Institutional Equities as part of their India Conference 2026, will include 29 institutional investors from domestic and international asset management companies.

Jubilant Pharmova Limited has informed stock exchanges about receiving a significant tax demand order from the Income Tax Department. The pharmaceutical company disclosed this development under Regulation 30 of the SEBI Listing Obligations and Disclosure Requirements Regulations, 2015.

Tax Demand Details

The Income Tax Department, DCIT/ACIT (Central), Moradabad, has raised a tax demand of ₹22.10 crores against Jubilant Pharmova for the financial year 2020. The order was dated December 27, 2025, with the company receiving it on December 30, 2025, at 4:23 PM (IST).

Basis of Tax Demand

The tax demand primarily arises from several issues identified by the Income Tax Department:

• Arithmetical errors and mistakes apparent from records
• Disallowances of expenses and deductions
• Transfer pricing adjustments
• Ignoring the contentions presented by the company

Company's Response Strategy

Jubilant Pharmova has expressed strong disagreement with the tax demand, stating that it suffers from mistakes apparent from records and was made while ignoring the company's contentions. The company has outlined its response strategy to challenge the order.

Management Outlook

The company maintains confidence in its position, believing that the impugned tax demand will likely be deleted post the redressal process. Jubilant Pharmova does not anticipate any material financial implications from this matter, indicating management's confidence in successfully challenging the order through appropriate legal channels.

The disclosure was made by Company Secretary Naresh Kapoor on December 31, 2025, ensuring compliance with regulatory requirements and keeping stakeholders informed about this significant development.